Bentley University is a private co-educational university in Waltham, Massachusetts, 9 miles west of Boston, focused on business. Founded in 1917 as a school of accounting and finance in Boston's Back Bay neighborhood, Bentley moved to Waltham in 1968. Bentley awards bachelor of science degrees in 11 business fields and bachelor of arts degrees in 6 arts and science disciplines. The graduate school emphasizes the impact of technology on business practice, and offers PhD programs in Business and Accountancy, the Bentley MBA with 16 areas of concentration, an integrated MS+MBA, 7 Master of Science degrees, and custom executive education programs.Bentley's athletic teams compete in Division II of the NCAA and is known collectively as the Bentley Falcons. They compete in the Northeast-10 Conference. Wikipedia.
News Article | April 10, 2017
MADISON, Wis., April 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J. Swirsky and Frederick W. Driscoll to its board of directors. “Both Fred and Doug bring extensive operational and industry experience that should prove invaluable to Cellectar as we enter this next phase of the company’s development,” said Jim Caruso, president and CEO of Cellectar Biosciences. “We look forward to working with both and benefitting from their contributions.” Douglas J. Swirsky has served as president and chief executive officer of GenVec, Inc. since 2013, and also serves as a member of GenVec's board of directors. Mr. Swirsky also currently serves as chairman of the board of Fibrocell Science, Inc. From 2006 through 2014, he served as senior vice president, chief financial officer, treasurer and corporate secretary of GenVec. Prior to joining GenVec in September 2006, Mr. Swirsky worked at Stifel Nicolaus where he served as a managing director and the head of Life Sciences Investment Banking. Previously, Mr. Swirsky held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. He received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a certified public accountant and a CFA® charterholder. Frederick W. Driscoll served as chief financial officer at Flexion Therapeutics (Flexion) from 2013 to 2017, spearheading a successful IPO in 2014. Prior to joining Flexion, he was chief financial officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. Previously, Mr. Driscoll also served as chief financial officer from 2007 to 2008, and subsequently chief executive officer from 2008 to 2009, at Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company that was acquired by GlaxoSmithKline; and chief executive officer at OXiGENE, Inc., a biopharmaceutical company, from 2000 to 2006. He has also served as chairman of the board and audit committee chair at OXiGENE and as a member of the audit committee for Cynapsus, which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma, as well as a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical-stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com. This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
News Article | April 17, 2017
Wilmington Trust, N.A. hired Joshua Stowell as senior trust sales representative for its Global Loan Agency Services group in the Global Capital Markets division. Based in the company’s Boston office, he will focus on expanding loan agency services to alternative capital providers, business development corporations, and direct lenders. Stowell will also sell successor loan agency services. Stowell has more than a decade of experience in finance. He joins Wilmington Trust from U.S. Bank, where he was a business development officer responsible for selling domestic corporate trust products and services including loan agency, custody, CLO trustee, and middle-office services. Prior to that, he was a manager of collateralized debt obligation (CDO) analytics at U.S. Bank, overseeing a group of analysts and creating complex CDO models for structured deals. “The addition of Josh to our Global Loan Agency Services business builds on our status as a trusted provider of independent loan agency services in the U.S. and Europe,” said Pat Trainor, senior vice president and sales manager of Global Capital Markets. “Josh developed a strong reputation in the syndicated and middle market loan space by leveraging his valuable experience in both transaction administration and business development. “Josh will work in close collaboration with Chris Monigle, our veteran client development officer. Together, they will be a powerful business development team in this space.” Stowell earned a Bachelor of Science in Finance from Bentley University, and also studied at the Vienna University of Economics and Business. He is based in Wilmington Trust’s Boston office, located at 280 Congress St., and can be reached at (617) 457-2067. ABOUT WILMINGTON TRUST Wilmington Trust, N.A. provides Corporate and Institution services including institutional trustee, agency, asset management, retirement plan services, and administrative services for clients worldwide who use capital markets financing structures. The corporate and institutional division is distinguished from many competitors by its status as a core business of Wilmington Trust, as well as the experience and expertise of its global staff and its multi-jurisdictional presence. Wilmington Trust also provides Wealth Advisory services with a wide array of personal trust, financial planning, fiduciary, asset management, and family office solutions designed to help high-net-worth individuals and families grow, preserve, and transfer wealth. Wilmington Trust has clients in all 50 states and in more than 90 countries, with offices throughout the United States and internationally in London, Dublin, and Frankfurt. For more information, visit http://www.WilmingtonTrust.com. Wilmington Trust is a registered service mark. Wilmington Trust Corporation is a wholly owned subsidiary of M&T Bank Corporation. Wilmington Trust Company, operating in Delaware only, Wilmington Trust, N.A., M&T Bank and certain other affiliates, provide various fiduciary and non-fiduciary services, including trustee, custodial, agency, investment management and other services. International corporate and institutional services are offered through Wilmington Trust Corporation's international affiliates. Loans, credit cards, retail and business deposits, and other business and personal banking services and products are offered by M&T Bank, member FDIC.
News Article | April 26, 2017
CHICAGO, April 26, 2017 (GLOBE NEWSWIRE) -- North American Company for Life and Health Insurance® is proud to announce the appointment of Steve Zimmerman as Sales Vice President. He will support independent life insurance agencies in his territory on implementing North American’s proven Partner Program, which helps Partner Agencies grow their business, in addition to consulting sales and marketing strategies, recruiting, and case placement. “Steve joins us with great experience and a track record of success managing long-term relationships with brokerage distributors and driving overall sales and profitability,” said Garth A. Garlock, Senior Vice President & Chief Distribution Officer. “In addition to his professional achievements, his passion for our business and alignment with our culture make him a terrific fit for the role.” Zimmerman will be responsible for assisting insurance agencies primarily in the Northeast quadrant of the United States, including the following key states: Maryland, Pennsylvania, Delaware, New Jersey, Connecticut, Massachusetts, New Hampshire, Vermont and Maine. Prior to joining North American Company, Zimmerman was Regional Sales Director for Transamerica. Zimmerman has earned designations for Certified Financial Planner (CFP), Chartered Life Underwriter (CLU), Chartered Financial Consultant (ChFC) and Accredited Estate Planner (AEP). He holds a Bachelor of Science in marketing and management from Bentley University. ABOUT NORTH AMERICAN COMPANY North American Company for Life and Health Insurance is a member of Sammons® Financial Group, Inc. Since 1886, North American has established a tradition of providing quality insurance products to consumers throughout the U.S. We offer a comprehensive portfolio of term, universal life, and indexed universal life insurance products. North American also offers a wide variety of traditional fixed and fixed index annuities and consistently ranks among the top fixed index annuity carriers in the U.S.1 In 2016, we ranked number 10 in life insurance sales, as part of Sammons Financial Group.2 For more information, please visit www.northamericancompany.com. Sammons® Financial Group is comprised of North American Company for Life and Health Insurance®, Midland National® Life Insurance Company, including its divisions, Sammons Annuity GroupSM and Sammons® Corporate Markets Group, Sammons Retirement Solutions® Inc. and Sammons Financial Network® LLC, member FINRA. 1 Source: AnnuitySpecs, Quarterly Indexed Sales & Market Report 2 Source: LIMRA International, U.S. Retail Individual Life Insurance Sales, fourth quarter 2016 results. Sales based on annualized premium plus excess.
News Article | April 27, 2017
BEDFORD, MA--(Marketwired - Apr 27, 2017) - Mass Innovation Nights (MIN) and The MITRE Corporation are collaborating to host #MIN98, an IoT-focused startup showcase and networking event, on Wednesday, May 10th from 6:00 p.m. to 8:30 p.m. The event will be held at MITRE's Massachusetts headquarters, 202 Burlington Road, Bedford, MA. "Mass Innovation Nights 98 will be our third event with MITRE, and we appreciate their commitment to supporting the local innovation community," said Bobbie Carlton, the founder of Innovation Nights, and Innovation Women. "MITRE continues to demonstrate this commitment to innovation in the Boston region." "We continue to see value in supporting local entrepreneurship events," said Pete Sherlock, MITRE senior vice president and chief operating officer. "Engaging with the innovation community is essential to our public interest mission. We're addressing complex challenges of national and global significance and access to local startups is a key part of that. Our role for our government sponsors is to be a bridge for innovation." Mass Innovation Nights #98 features experts, networking, tabletop presentations with new local products and presentations from the winners of online voting. The event is open to the public and free to attend. Two student-founded startups from Bentley University, Sales Sparks and Sooshay, will also present. Guests are encouraged to use hashtag #MIN98 and @MassInno to share their photos and commentary. Companies showcasing new products at #MIN98 include: There will also be experts from: Mass Innovation Nights gatherings typically generate hundreds of Tweets, Facebook posts, blogs, and videos, and are key visibility drivers for the launching companies. To attend, please RSVP by May 2, 2017. About Mass Innovation Nights Mass Innovation Nights (MIN) offers an opportunity for people interested in innovative new products to connect live and online. Each month, different companies launch new products with Innovation Nights and the social media community helps spread the word. The popular product launch party and networking event draws attendees from the entire region. Over the past 8 years, it has launched almost 1000 new products which have collectively received more than $1.3 billion in funding. Follow MIN on Twitter or visit the website at mass.innovationnights.com/. About MITRE MITRE is a not-for-profit organization that operates research and development centers sponsored by the federal government. Learn more.
News Article | May 15, 2017
Mr. Freda joined the Hamilton Board of Directors in June, 2014 and chairs the Board's Audit Committee. Mr. Brown has been a member of the Board since Hamilton's establishment in December 2013 and is Chairman of the Finance and Governance Committee. "It is with regret that we have accepted Brian's resignation from Hamilton," said Mr. Freda. "He is an industry icon with a well-deserved reputation for visionary leadership. We have had the privilege of experiencing this first-hand at Hamilton. "However, we have in David an experienced industry CEO who has been with the Company since inception. He is an ideal resource to lead Hamilton through this transition. "With a superlative management team, and a Board of Directors representing a cross section of disciplines from the insurance, finance and technology industries, we are well-prepared to continue to execute our mission of writing the future of risk. "In addition, our relationship with Two Sigma, our technology and investment partner, has been an extremely productive one since Hamilton's launch at the end of 2013. Our experience with Attune, the technology-enabled company established with Two Sigma and AIG, has demonstrated the huge potential in applying data science and analytics to transform the underwriting process. "We are all excited about the potential for ongoing growth and development at Hamilton." Mr. Freda concluded his distinguished career at Deloitte LLP in 2014, having worked for the firm for 40 years following his graduation from Bentley University in Waltham, Massachusetts. At Deloitte, Mr. Freda served on a wide range of multinational engagements, interacting with clients' audit committees, boards of directors and senior management to address critical, strategic issues. Mr. Freda's many senior positions at Deloitte included Chairman of the Risk Committee and the Audit Committee of Deloitte Touche Tohmatsu Limited's Board of Directors, Managing Partner of Deloitte's U.S. client initiatives, and Regional Managing Partner of the Northeast, Deloitte's largest U.S. region. Mr. Freda has been involved in many industry associations and community organizations, including the Board of Trustees of Bentley University. He is a member of the Board of Directors of The Guardian Insurance Company of America and State Street Corporation. Mr. Brown served as the Chief Executive Officer of Flagstone Reinsurance Holdings Ltd. from its foundation in October 2005 until November 2012. He previously served as Chief Executive of Centre Solutions from 1994 until 1997. Before joining Centre Solutions, he was a Partner with Ernst & Young. He has been Chairman of the Board at the Bermuda Stock Exchange since 2000. Mr. Brown is a Fellow of the Institute of Chartered Accountants in England and Wales. He is also a member of the Institute of Chartered Accountants of Bermuda. Hamilton Insurance Group is the Bermuda-based holding company for property and casualty insurance and reinsurance operations in Bermuda, the U.S. and at Lloyd's. The company leverages analytics and research to create underwriting and investment value for its clients and shareholders. For more information, please visit www.hamiltongroup.com | Twitter: @HamiltonInsures | LinkedIn: https://www.linkedin.com/company/hamilton-insurance-group To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hamilton-insurance-group-appoints-william-c-freda-as-chairman-and-david-a-brown-as-interim-group-ceo-300457280.html
News Article | May 10, 2017
Most of the new drugs approved by the FDA since 2010 arose from basic scientific research that was initiated in the 1970s or 1980s, a new study from Bentley University has found. The analysis shows that development of new targeted and biological therapeutics rest on the maturation of basic science over decades. The research, published today in the journal PLOS One, appears as scientists are increasingly concerned about federal support for basic biomedical research. The PLOS One article, titled "Timelines of translational science: From technology initiation to FDA approval," uses an analytical model for the growth of basic research to examine the relationship between the progress of research and approval of new drugs based on this work. The study from Bentley's Center for Integration of Science and Industry examined all of the drugs approved by the FDA from 2010-2014. The analysis shows that basic biomedical research on drug targets follows predictable patterns of growth and maturation, and that the ability to successfully translate this science into new therapeutics depends on first achieving a certain level of maturation. "While we celebrate the 'a ha' moment of scientific discovery and invention, such moments are only the point of initiation for the basic research required to develop new drugs," said Dr. Laura McNamee, the lead author of the paper and a research associate in Bentley's Center for Integration of Science and Industry. "Our analysis shows that very few targeted or biological therapeutics emerge from this basic research until it becomes established." The paper published showed that the efficiency of drug development improved significantly when the enabling science passed an established point defined by the analytical model. No targeted or biological products were approved before this point, and clinical development of approved products was three years shorter for products that entered clinical trial trials after this point. "Translational medicine remains a largely empirical process, and we are only beginning to apply the theories and analytical tools of systems engineering and technology management to improve the efficiency of translational science," said Dr. Fred Ledley, founding director of the center and a co-author of the paper. "Modeling the process of translational science, it is clear that greater emphasis needs to be placed on expediting the growth of basic biomedical research to improve the efficiency, timelines, and cost of bringing new cures to market."
News Article | May 10, 2017
TraceLink, which achieved revenue growth of 585 percent from 2012 to 2015, was ranked as the #8 fastest growing company from Massachusetts on the 2016 Deloitte Technology Fast 500™, and ranked #4 among the fastest growing software companies headquartered in the state. "We expect to grow our team by more than 100 new employees over the course of 2017, with a strong focus on increasing our headcount at our corporate headquarters in North Reading, Mass., while expanding our presence in our London office for the international market," added Dahod. "As TraceLink's newly appointed Chief People Officer, I look forward to ensuring that the organization not only meets the impressive growth demands of an industry-leading company, but that we continue to engage with and develop our current employees while ensuring new talent brings an exceptionally high level of quality to the team," said Camelio. "The addition of Regina and Jeff joining me at TraceLink is a testament to our accomplishments in constructing exceptional organizations and the understanding that TraceLink is looking for A-players who want to be a part of a shared passion in securing the global pharmaceutical supply chain." Nick Camelio, Chief People Officer Nick Camelio joins TraceLink from Demandware, a publicly traded cloud-based ecommerce solution for some of the world's top brands and retailers, where he served as Chief People Officer and Senior Vice President for Human Resources. Camelio was an instrumental member of the Executive Team at Demandware, aiding in the company's growth from $56.5 million to $237.3 million in revenue, the Company's successful IPO in 2012, and increased employee headcount from 100 to more than 1,000 worldwide. Prior to joining Demandware, Camelio served as Senior Vice President of Human Resources at Salary.com, where he established the Global Human Capital Management function to support the advancement and development of Salary.com's business and people after a successful IPO in 2007. Previously, Camelio held HR leadership positions at BrassRing Inc., Vignette Corporation, IBM and Lotus Development Corporation. Camelio holds a Bachelor's degree from Bentley University, and is a member of the Society for Human Resource Management (SHRM). He is also a Certified Compensation Professional (CCP) and Global Remuneration Professional (GRP) through WorldatWork, and a certified Human Capital Strategist. Regina O'Brien, Vice President, Learning and Human Resource Operations Regina O'Brien joins TraceLink as the former Vice President for Human Resource Operations at Demandware, where she was responsible for Demandware's HR Center of Excellence, including HRIS, compensation (cash and equity), payroll, corporate training, and organizational design and development. Prior to joining Demandware, O'Brien was the Human Resources Generalist & Business Partner at Brookfield Renewable Power, where she focused on union-management-corporate relations. Previously, O'Brien worked at Salary.com, Akamai and AOL. O'Brien holds a Bachelor's degree in Government and International Relations from Clark University, and a General Course Certification from the London School of Economics. She is a Certified Compensation Professional (CCP), Global Remuneration Professional (GRP), SHRM Senior Certified Professional (SHRM-SCP), and a Certified Kolbe Consultant. Jeff Sa, Senior Director, Global Talent Acquisition Jeff Sa brings over 25 years of experience in software recruiting for some of the strongest Cloud and SaaS organizations in the industry. Sa was formerly the Senior Director, Global Talent Acquisition for Demandware, where he was responsible for strategic and tactical management of the company's Talent Acquisition organization and managed all executive level talent recruitment. Prior to his time at Demandware, Sa headed up North America Technical Staffing at BMC Software (formerly BladeLogic) and previously led staffing efforts for various EMC divisions, where he spearheaded recruiting initiatives for EMC's first Cloud and SaaS products. Sa holds a Bachelor's degree focused in Human Resources from the University of Massachusetts at Amherst. About TraceLink TraceLink is the World's Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte's Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com or follow us on LinkedIn, Twitter and Facebook. TraceLink is funded by Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tracelink-expands-leadership-team-with-chief-people-officer-and-addition-of-new-human-resources-leaders-from-demandware-300454501.html
Everett D.L.,Bentley University
Wiley Interdisciplinary Reviews: Cognitive Science | Year: 2012
Pirahã is a language isolate of the Brazilian Amazon. Among the lessons it has to teach us about human language and the mind, two are highlighted here. The first is that recursion is not a necessary condition for human syntax, because there is no evidence for recursive sentential syntax in the language. This is a stark counterexample to the claims of Chomsky and others. The second lesson is that the influence of culture on Pirahã grammar, coupled with much established and newer research, indicates that the idea of an innate, universal grammar has little if any role to play in our understanding of the nature, origins, and use of human language. © 2012 John Wiley & Sons, Ltd.
Chau M.,University of Hong Kong |
Xu J.,Bentley University
MIS Quarterly: Management Information Systems | Year: 2012
The increasing popularity of Web 2.0 has led to exponential growth of user-generated content in both volume and significance. One important type of user-generated content is the blog. Blogs encompass useful information (e.g., insightful product reviews and information-rich consumer communities) that could potentially be a gold mine for business intelligence, bringing great opportunities for both academic research and business applications. However, performing business intelligence on blogs is quite challenging because of the vast amount of information and the lack of commonly adopted methodology for effectively collecting and analyzing such information. In this paper, we propose a framework for gathering business intelligence from blogs by automatically collecting and analyzing blog contents and bloggers' interaction networks. Through a system developed using the framework, we conducted two case studies with one case focusing on a consumer product and the other on a company. Our case studies demonstrate how to use the framework and appropriate techniques to effectively collect, extract, and analyze blogs related to the topics of interest, reveal novel patterns in the blogger interactions and communities, and answer important business intelligence questions in the domains. The framework is sufficiently generic and can be applied to any topics of interest, organizations, and products. Future academic research and business applications related to the topics examined in the two cases can also be built using the findings of this study.
Stavrulaki E.,Bentley University
International Journal of Production Economics | Year: 2011
We study a retailer's inventory policy for two products. The products are substitutable and have inventory dependent demand, so a higher inventory level of a product increases its sales. We model the joint effect of demand stimulation and product substitution on inventory decisions by considering a single-period, stochastic demand setting. We provide the first order optimality conditions for the profit maximizing order quantities and interpret them using marginal analysis. We also consider two heuristic solutions that separately account for either demand stimulation or product substitution. Our numerical analysis reveals that the optimal policy by appropriately using sales information that quantifies substitution and demand stimulation can produce significantly higher profits. The profit benefits are lessened under certain circumstances, such as when the two products have similar critical fractile values, suggesting that in such instances the heuristics may be used effectively. © 2010 Elsevier B.V. All rights reserved.